军事知识服务平台
多组学解析非粒细胞缺乏免疫抑制与病毒相关侵袭性肺曲霉病的免疫异质性:从机制到精准诊疗
Multi-omics dissection of immune heterogeneity between non-neutropenic immunosuppressive and virus-associated invasive pulmonary aspergillosis: from mechanisms to precision medicine
摘要 侵袭性肺曲霉病(IPA)的宿主谱已从经典的粒细胞缺乏(粒缺)扩展至非粒缺免疫抑制及病毒相关IPA(VAPA),两类宿主免疫病理机制差异较大,常规诊疗策略疗效欠佳。本文系统阐述了基因组学、转录组学、蛋白质组学及代谢组学在非粒缺IPA与VAPA中的研究进展,对比两类宿主在宿主-病原体互作、免疫应答模式及组织损伤机制方面的差异,评估多组学联合及机器学习辅助建立预测模型在早期诊断与预后判断中的转化价值。非粒缺IPA以免疫抑制、低水平慢性炎症及能量代谢障碍为核心特征,表现为巨噬细胞M2极化、T淋巴细胞耗竭及哺乳动物雷帕霉素靶蛋白(mTOR)通路受抑;VAPA则以免疫失衡、细胞因子风暴及代谢应激失代偿为特点,表现为Ⅰ型干扰素通路持续激活、中性粒细胞胞外诱捕网(NETs)过度激活及IDO1-AHR通路异常。多组学联合机器学习模型可辅助早期诊断,优于单一标志物。基于多组学的免疫内型分型为IPA个体化诊疗提供新策略,未来需通过前瞻性多中心队列验证标志物效能并优化免疫调节干预时机。
Abstract:
The host spectrum of invasive pulmonary aspergillosis(IPA)has broadened from classical neutropenic patients to include non-neutropenic immunosuppressive hosts and those with virus-associated IPA(VAPA). These two host groups exhibit distinct immunopathological mechanisms,posing substantial challenges to conventional diagnostic and therapeutic strategies. This review systematically summarizes recent advances in genomics,transcriptomics,proteomics,and metabolomics applied to IPA in non-neutropenic hosts and VAPA,compares host-pathogen interactions,immune response patterns,and tissue injury mechanisms between the two groups,and evaluates the translational value of integrating multi-omics with machine learning for early diagnosis and prognosis. IPA in non-neutropenic hosts is characterized by immunosuppression,low-grade chronic inflammation,and energy metabolism dysfunction,manifesting as M2 macrophage polarization,T-cell exhaustion,and mTOR pathway inhibition. In contrast,VAPA features immune dysregulation,cytokine storms,and metabolic stress decompensation,with sustained type I interferon activation,excessive NETs,and IDO1-AHR pathway aberrations. Combining multi-omics with machine learning models improves diagnostic performance,significantly outperforming single biomarkers. Multiomics-based immune endotype stratification offers novel strategies for individualized IPA management. Future prospective multicenter cohort studies are warranted to validate biomarker efficacy and optimize the timing of immunomodulatory interventions.